Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 14/20 | 0.48 |
| ▸ | MET | P08581 | 5/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | TEK | Q02763 | 1/20 | 0.45 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.45 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14742683 | 0.87 | GCK (0.53) | GCKKDRMETAXLNTRK1 | |
| SCHEMBL14976311 | 0.84 | KDR (0.61) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL30965184 | 0.84 | KDR (0.61) | KDRMETNTRK1TEKNTRK3 | |
| SCHEMBL14975595 | 0.83 | GCK (0.47) | GCKKDRMETAXLNTRK1 | |
| SCHEMBL13788628 | 0.80 | GCK (0.48) | GCKKDRBRAF | |
| SCHEMBL16036583 | 0.77 | CSF1R (0.48) | GCKKDRMETAXL | |
| SCHEMBL16038768 | 0.75 | CDK8 (0.48) | GCK | |
| SCHEMBL6426864 | 0.75 | KDR (0.50) | GCKKDRAXLTEKNTRK3 | |
| SCHEMBL141721 | 0.75 | MET (0.81) | KDRMETAXLNTRK1TEK | |
| SCHEMBL12281841 | 0.75 | MAPK14 (0.51) | GCKKDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9387202-B2 | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2016-07-12 | — | — | US | disclosed |
| US-9387202-B2 | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150148380-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC | 2015-05-28 | — | — | US | disclosed |
| US-20150148380-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC | 2015-05-28 | — | — | US | disclosed |
| US-8921565-B2 | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921565-B2 | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2782577-A2 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | Deciphera Pharmaceuticals, LLC. (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20130317066-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2013078295-A2 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013078295-A2 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148380-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | MKI67, TYMP, CCNA1 | GCK 727/4885KDR 2384/4885MET 2197/4885 |
| US-20130317066-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | MKI67, TYMP, CCNA1 | GCK 727/4885KDR 2384/4885MET 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.